Screening for type 2 diabetes: An update of the evidence

Diabetes, Obesity and Metabolism

Volumn 12, Issue 10, 2010, Pages 838-844

  Simmons, R K ^a   Echouffo Tcheugui, J B ^a   Griffin, S J ^a  

^a INSTITUTE OF METABOLIC SCIENCE   (United Kingdom)

Author keywords

Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; CHOLESTEROL; GLUCOSE; ORAL ANTIDIABETIC AGENT;

BEHAVIOR; BEHAVIOR MODIFICATION; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DIABETES CONTROL; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; EVIDENCE BASED PRACTICE; FOLLOW UP; HAZARD RATIO; HIGH RISK POPULATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; REVIEW; SCREENING; TREATMENT OUTCOME;

EID: 77956142355     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01244.x     Document Type: Review

References (91)

1. The Diabetes 2009, IDF., 4th edn., Brussels, Atlas
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21:1414-1431.
3. UK Prospective Diabetes Study 6. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res 1990, 13:1-11. UKPDS.
4. Chang HJ, Kuo HS, Tung TH, Chou P, Chen TH. Evaluation of a population-based screening for type 2 diabetes: a community-based screening project in Puli, Taiwan. Prev Med 2000, 31:396-402.
5. Kuo HS, Chang HJ, Chou P, Teng L, Chen TH. A Markov chain model to assess the efficacy of screening for non-insulin dependent diabetes mellitus (NIDDM). Int J Epidemiol 1999, 28:233-240.
6. Waugh N, Scotland G, McNamee P. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess 2007, 11:1-125.
7. Glumer C, Yuyun M, Griffin S. What determines the cost-effectiveness of diabetes screening? Diabetologia 2006, 49:1536-1544.
8. Wareham NJ, Griffin SJ. Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteria. BMJ 2001, 322:986-988.
9. Goyder E, Wild S, Fischbacher C, Carlisle J, Peters J. Evaluating the impact of a national pilot screening programme for type 2 diabetes in deprived areas of England. Fam Pract 2008, 25:370-375.
10. Cochrane AL, Holland WW. Validation of screening procedures. Br Med Bull 1971, 27:3-8.
11. http://www.screening.nhs.uk/criteria, National Screening Committee, Available from URL:, Accessed 19 March 2010.
12. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87:4-14.
13. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992, 15:815-819.
14. Thompson TJ, Engelgau MM, Hegazy M. The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults. Diabet Med 1996, 13:337-340.
15. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 1997, 20:163-169.
16. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
17. Goyder EC, McNally PG, Drucquer M, Spiers N, Botha JL. Shifting of care for diabetes from secondary to primary care, 1990-5: review of general practices. BMJ 1998, 316:1505-1506.
18. Gillies CL, Abrams KR, Lambert PC. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007, 334:299.
19. Lindstrom J, Ilanne-Parikka P, Peltonen M. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006, 368:1673-1679.
20. Li G, Zhang P, Wang J. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008, 371:1783-1789.
21. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374:1677-1686. Diabetes Prevention Program Research Group
22. Absetz P, Oldenburg B, Hankonen N. Type 2 diabetes prevention in the real world: three-year results of the GOAL lifestyle implementation trial. Diabetes Care 2009, 32:1418-1420.
23. Kilkkinen A, Heistaro S, Laatikainen T. Prevention of type 2 diabetes in a primary health care setting. Interim results from the Greater Green Triangle (GGT) Diabetes Prevention Project. Diabetes Res Clin Pract 2007, 76:460-462.
24. Ackermann RT, Finch EA, Brizendine E, Zhou H, Marrero DG. Translating the Diabetes Prevention Program into the community. The DEPLOY Pilot Study. Am J Prev Med 2008, 35:357-363.
25. Ruge T, Nystrom L, Lindahl B. Recruiting high-risk individuals to a diabetes prevention program: how hard can it be? Diabetes Care 2007, 30:e61.
26. Ackermann RT, Marrero DG, Hicks KA. An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes. Diabetes Care 2006, 29:1237-1241.
27. Hill JO. Can a small-changes approach help address the obesity epidemic? A report of the Joint Task Force of the American Society for Nutrition, Institute of Food Technologists, and International Food Information Council. Am J Clin Nutr 2009, 89:477-484.
28. Simmons RK, Harding AH, Jakes RW, Welch A, Wareham NJ, Griffin SJ. How much might achievement of diabetes prevention behaviour goals reduce the incidence of diabetes if implemented at the population level? Diabetologia 2006, 49:905-911.
29. Unal B, Critchley JA, Capewell S. Small changes in United Kingdom cardiovascular risk factors could halve coronary heart disease mortality. J Clin Epidemiol 2005, 58:733-740.
30. http://www.diabetes.fi/tiedoston_katsominen.php?dok_id=181, Finnish Diabetes Association, The Development Programme for the Prevention and Care of Diabetes in Finland 2000-2010 (DEHKO). Available from URL
31. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004, 164:2147-2155.
32. Simmons RK, Griffin SJ, Wareham NJ. Researching how to realize the potential of diabetes prevention. Diabet Med 2007, 24:1055-1057.
33. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985, 14:32-38.
34. Ramachandran A, Snehalatha C, Yamuna A, Mary S, Ping Z. Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care 2007, 30:2548-2552.
35. Herman WH, Hoerger TJ, Brandle M. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005, 142:323-332.
36. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005, 143:251-264.
37. Herman WH, Hoerger TJ, Hicks K. Managing people at high risk for diabetes. Ann Intern Med 2006, 144:66-67.
38. Engelgau MM. Trying to predict the future for people with diabetes: a tough but important task. Ann Intern Med 2005, 143:301-302.
39. Teutsch S. The cost of preventing diabetes: what do we know and what do we need to know? Diabetes Care 2003, 26:238-239.
40. Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther 2004, 26:304-321.
41. Wong TY, Liew G, Tapp RJ. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet 2008, 371:736-743.
42. Engelgau MM, Narayan KM, Herman WH. Screening for type 2 diabetes. Diabetes Care 2000, 23:1563-1580.
43. Phillips LS, Ziemer DC, Kolm P. Glucose challenge test screening for prediabetes and undiagnosed diabetes. Diabetologia 2009, 52:1798-1807.
44. Davies M, Alban-Davies H, Cook C, Day J. Self testing for diabetes mellitus. BMJ 1991, 303:696-698.
45. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009, 32:1327-1234. International Expert Committee
46. Echouffo-Tcheugui JB, Simmons RK, Williams KM. The ADDITION-Cambridge trial protocol: a cluster-randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients. BMC Public Health 2009, 9:136.
47. Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003, 26:725-731.
48. Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ. Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes Metab Res Rev 2000, 16:164-171.
49. Chamnan P, Simmons RK, Khaw KT, Wareham NJ, Griffin SJ. Estimating the population impact of screening strategies for identifying and treating people at high risk of cardiovascular disease: modelling study. BMJ 340:c1693.
50. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
51. Gerstein HC, Miller ME, Byington RP. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
52. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. ADVANCE.
53. Duckworth W, Abraira C, Moritz T. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
54. Currie CJ, Peters JR, Tynan A. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 375:481-489.
55. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998, 317:703-713. UKPDS.
56. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000, 355:253-159. HOPE.
57. Colhoun HM, Betteridge DJ, Durrington PN. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
58. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997, 20:614-620.
59. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
60. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005, 91(Suppl. 5):v1-v52. JBS.
61. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
62. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 2000, 24(Suppl. 3):S6-S11.
63. Webb DR, Khunti K, Srinivasan B. Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening. Trials 2010, 11:16.
64. Sandbaek A, Griffin SJ, Rutten G. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia 2008, 51:1127-1134.
65. Echouffo-Tcheugui JB, Sargeant LA, Prevost AT. How much might cardiovascular risk be reduced by intensive therapy in people with screen-detected diabetes? Diabet Med 2008, 25:1433-1439.
66. Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. Br J Gen Pract 2009, 59:43-48.
67. The Audit Commission. Testing times. A review of diabetes services in England and Wales 2000, http://www.audit-commission.gov.uk/SiteCollectionDocuments/AuditCommissionReports/NationalStudies/nrdiabet.pdf, London: Audit Commission, Available from URL
68. Campbell SM, Reeves D, Kontopantelis E, Sibbald B, Roland M. Effects of pay for performance on the quality of primary care in England. N Engl J Med 2009, 361:368-378.
69. Calvert M, Shankar A, McManus RJ, Lester H, Freemantle N. Effect of the quality and outcomes framework on diabetes care in the United Kingdom: retrospective cohort study. BMJ 2009, 338:b1870.
70. Gulliford MC, Latinovic R, Charlton J. Diabetes diagnosis, resource utilization, and health outcomes. Am J Manag Care 2008, 14:32-38.
71. Home P. The challenge of poorly controlled diabetes mellitus. Diabetes Metabolism 2003, 29:101-109. (2 Pt 1):
72. Sargeant LS, Simmons RK, Barling RS, Butler R, Williams KM, Prevost AT, Kinmonth AL, Wareham NJ, Griffin SJ. Who attends a UK diabetes screening programme? Findings from the ADDITION-Cambridge study. Diabetic Medicine 2010, in press.
73. Graffy J, Grant J, Williams K. More than measurement: practice team experiences of screening for type 2 diabetes. Fam Pract 2010, 27:386-394.
74. Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Low yield of population-based screening for Type 2 diabetes in the Netherlands: the ADDITION Netherlands study. Fam Pract 2007, 24:555-561.
75. Park PJ, Griffin SJ, Duffy SW, Wareham NJ. The effect of varying the screening interval on false positives and duration of undiagnosed disease in a screening programme for type 2 diabetes. J Med Screen 2000, 7:91-96.
76. Adriaanse MC, Snoek FJ, Dekker JM. No substantial psychological impact of the diagnosis of Type 2 diabetes following targeted population screening: The Hoorn Screening Study. Diabet Med 2004, 21:992-998.
77. Adriaanse MC, Snoek FJ. The psychological impact of screening for type 2 diabetes. Diabetes Metab Res Rev 2006, 22:20-25.
78. Adriaanse MC, Dekker JM, Spijkerman AM. Health-related quality of life in the first year following diagnosis of Type 2 diabetes: newly diagnosed patients in general practice compared with screening-detected patients. The Hoorn Screening Study. Diabet Med 2004, 21:1075-1081.
79. Edelman D, Olsen MK, Dudley TK, Harris AC, Oddone EZ. Impact of diabetes screening on quality of life. Diabetes Care 2002, 25:1022-1026.
80. Eborall H, Davies R, Kinmonth AL, Griffin S, Lawton J. Patients' experiences of screening for type 2 diabetes: prospective qualitative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 2007, 335:490.
81. Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton S. Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 2007, 335:486.
82. Paddison CAM, Eborall HC, Sutton SR. Are people with negative diabetes screening tests falsely reassured? A parallel group cohort study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 2009, 339:b4535.
83. Schwarz PE, Lindstrom J, Kissimova-Scarbeck K. The European perspective of type 2 diabetes prevention: diabetes in Europe-prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project. Exp Clin Endocrinol Diabetes 2008, 116:167-172.
84. Putting Prevention First. Vascular Checks: Risk Assessment and Management. 2008, Department of Health., London: Department of Health
85. Gillies CL, Lambert PC, Abrams KR. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ 2008, 336:1180-1185.
86. Goyder EC. Screening for and prevention of type 2 diabetes. BMJ 2008, 336:1140-1141.
87. Kahn R, Alperin P, Eddy D. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 375:1365-1374.
88. Mann E, Prevost AT, Griffin S. Impact of an informed choice invitation on uptake of screening for diabetes in primary care (DICISION): trial protocol. BMC Public Health 2009, 9:63.
89. Marteau TM, Mann E, Prevost AT. Impact of an informed choice invitation on uptake of screening for diabetes in primary care (DICISION): a randomised trial. BMJ 2010, 340:c2138.
90. Heath I. Life and Death. It is not wrong to say no. BMJ 2009, 338:b2529.
91. Thompson SG, Ashton HA, Gao L, Scott RA. Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study. BMJ 2009, 338:b2307.